Literature DB >> 34845347

Entering the endgame for advanced RCC?

Louise Stone1.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 34845347     DOI: 10.1038/s41585-021-00547-0

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  2 in total

1.  Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.

Authors:  Vadim S Koshkin; Nicholas Henderson; Marihella James; Divya Natesan; Dory Freeman; Amanda Nizam; Christopher T Su; Ali Raza Khaki; Chelsea K Osterman; Michael J Glover; Ryan Chiang; Dimitrios Makrakis; Rafee Talukder; Emily Lemke; T Anders Olsen; Jayanshu Jain; Albert Jang; Alicia Ali; Tanya Jindal; Jonathan Chou; Terence W Friedlander; Christopher Hoimes; Arnab Basu; Yousef Zakharia; Pedro C Barata; Mehmet A Bilen; Hamid Emamekhoo; Nancy B Davis; Sumit A Shah; Matthew I Milowsky; Shilpa Gupta; Matthew T Campbell; Petros Grivas; Guru P Sonpavde; Deepak Kilari; Ajjai S Alva
Journal:  Cancer       Date:  2021-12-09       Impact factor: 6.860

2.  Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial.

Authors:  Meredith M Regan; Opeyemi A Jegede; Charlene M Mantia; Thomas Powles; Lillian Werner; Robert J Motzer; Nizar M Tannir; Chung-Han Lee; Yoshihiko Tomita; Martin H Voss; Elizabeth R Plimack; Toni K Choueiri; Brian I Rini; Hans J Hammers; Bernard Escudier; Laurence Albiges; Stephen Huo; Viviana Del Tejo; Brian Stwalley; Michael B Atkins; David F McDermott
Journal:  Clin Cancer Res       Date:  2021-11-10       Impact factor: 13.801

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.